ECSP20076576A - Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas - Google Patents

Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas

Info

Publication number
ECSP20076576A
ECSP20076576A ECSENADI202076576A ECDI202076576A ECSP20076576A EC SP20076576 A ECSP20076576 A EC SP20076576A EC SENADI202076576 A ECSENADI202076576 A EC SENADI202076576A EC DI202076576 A ECDI202076576 A EC DI202076576A EC SP20076576 A ECSP20076576 A EC SP20076576A
Authority
EC
Ecuador
Prior art keywords
binding proteins
receptor binding
cannabinoid receptor
proteins type
type
Prior art date
Application number
ECSENADI202076576A
Other languages
English (en)
Inventor
Nikolai Suslov
Antara Banerjee
Kacey Sachen
Robert Hoey
Andrea Fanjul
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP20076576A publication Critical patent/ECSP20076576A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Proteínas de unión al CB1 no naturales, aisladas, modificadas genéticamente que incluyen anticuerpos anti-CB1 o un fragmento de unión al antígeno de los mismos. Las proteínas de unión al CB1 son de utilidad en el tratamiento y diagnóstico de condiciones, enfermedades y trastornos mediados por CB1.
ECSENADI202076576A 2018-04-30 2020-11-27 Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas ECSP20076576A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862664882P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
ECSP20076576A true ECSP20076576A (es) 2021-12-30

Family

ID=67396963

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202076576A ECSP20076576A (es) 2018-04-30 2020-11-27 Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas

Country Status (20)

Country Link
US (2) US20220396620A1 (es)
EP (1) EP3787746A1 (es)
JP (2) JP7431750B2 (es)
KR (1) KR20210005051A (es)
CN (1) CN112218684A (es)
AR (1) AR114436A1 (es)
AU (1) AU2019264029A1 (es)
BR (1) BR112020022035A2 (es)
CA (1) CA3098416A1 (es)
CL (1) CL2020002793A1 (es)
CO (1) CO2020014681A2 (es)
EA (1) EA202092593A1 (es)
EC (1) ECSP20076576A (es)
MA (1) MA52504A (es)
MX (1) MX2020011498A (es)
PE (1) PE20210419A1 (es)
PH (1) PH12020551805A1 (es)
SG (1) SG11202010388SA (es)
TW (1) TW202003549A (es)
WO (1) WO2019211665A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210419A1 (es) 2018-04-30 2021-03-08 Takeda Pharmaceuticals Co Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
WO2023242843A1 (en) * 2022-06-17 2023-12-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peripheralization of centrally-acting cannabinoid-1 receptor antagonists by nanoparticles for the treatment metabolic related conditions
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
CA2915386A1 (en) * 2013-06-26 2014-12-31 Amgen Inc. Cb1 receptor antigen-binding proteins and uses thereof
WO2015148984A2 (en) * 2014-03-27 2015-10-01 Ruiyi Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
US10277406B1 (en) * 2014-09-05 2019-04-30 Digicert, Inc. Authentication process for issuing sequence of short-lived digital certificates
US10034865B2 (en) 2015-09-10 2018-07-31 Kashiv Pharma, Llc Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
AU2016330471B2 (en) * 2015-09-30 2022-09-29 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (CB1) receptor
PE20210419A1 (es) 2018-04-30 2021-03-08 Takeda Pharmaceuticals Co Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas

Also Published As

Publication number Publication date
KR20210005051A (ko) 2021-01-13
JP7431750B2 (ja) 2024-02-15
CL2020002793A1 (es) 2021-02-12
MX2020011498A (es) 2021-01-29
EP3787746A1 (en) 2021-03-10
TW202003549A (zh) 2020-01-16
SG11202010388SA (en) 2020-11-27
US11746155B2 (en) 2023-09-05
US20210198358A1 (en) 2021-07-01
CO2020014681A2 (es) 2020-12-10
EA202092593A1 (ru) 2021-02-12
WO2019211665A1 (en) 2019-11-07
PE20210419A1 (es) 2021-03-08
PH12020551805A1 (en) 2021-07-26
MA52504A (fr) 2021-04-28
CA3098416A1 (en) 2019-11-07
CN112218684A (zh) 2021-01-12
JP2021525059A (ja) 2021-09-24
BR112020022035A2 (pt) 2021-02-02
AU2019264029A1 (en) 2020-11-19
AR114436A1 (es) 2020-09-02
JP2024059646A (ja) 2024-05-01
US20220396620A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
ECSP20076576A (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
CO2019010503A2 (es) Plataforma de identificación de péptidos inmunogénicos personalizada
CL2020003096A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
CL2017002237A1 (es) Proteína de unión de il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
CL2019001434A1 (es) Proteínas de unión a antígeno que se unen al receptor de leptina. (divisional solicitud 201800946)
UY36539A (es) Proteínas de unión a icos
CO2019014286A2 (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
CO2019002550A2 (es) Anticuerpos anti-gm-csf y usos de los mismos
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
CO2021007882A2 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
CO2021008204A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso
CO2022019161A2 (es) Tubulisinas y conjugados de proteína-tubulisina
EA202192488A1 (ru) Антитела против tsg-6 и их применения
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
CO2021009689A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
CL2019001537A1 (es) Nuevos receptores de células t y terapia inmunológica que los utiliza.
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
ECSP22020678A (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares